Bringer ingelhand is facing more than 2000 lawsuits in the United States

Source: dingxiangyuan 2014-02-17 German pharmaceutical company bringer Ingelheim (BI) announced on February 13 that the company is facing more than 2000 legal proceedings in the United States, saying that the company's new type of stroke prevention drug dabigatran ester causes serious and fatal bleeding Bi confirmed the number of lawsuits reported by the German newspaper German business daily on February 13, adding that the risk of side effects of dabigatran ester is known and that the potential of drugs to save lives must be weighed "We are convinced that the research, development and sales of dabigatran ester are very careful and responsible," the company said in a written statement Dabigatran ester is a new anticoagulant The drug is intended to replace warfarin, which has been used for decades, to prevent strokes in patients with AF Like other anticoagulants, dabigatran axetil has the benefit of reducing the incidence of stroke, but it is also accompanied by the risk of bleeding, which can also lead to death Bringer Ingelheim cited a new FDA study that showed patients on dabigatran had a lower risk of serious bleeding than those on warfarin Dabigatran group achieved a sales revenue of 1.1 billion euros (US $1.5 billion) in 2012, the second year after its approval for marketing Its competitors include Bayer's and Johnson's rivaroxaban and Bristol Myers Squibb's and Pfizer's apixaban Source address: http://www.reuters.com/article/2014/02/13/us-boehringer-pradaxa-idusbrea1c0pw20140213